In head and neck squamous cell carcinoma (HNSCC), the anti-EGFR monoclonal antibody cetuximab has been proven to prolong overall survival in combination with radiotherapy [7] and to enhance response rates in recurrent/metastatic disease in combination with cisplatin or fluorouracil [8]. This evidence concerns the gene EGFR and metastatic neoplasm.